Cardiovascular Safety of Febuxostat or Allopurinol in Patients with Gout
Cardiovascular Safety of Febuxostat or Allopurinol in Patients with Gout
W. White,K. Saag,6 Autoren,L. Gunawardhana
2018 · DOI: 10.1056/NEJMoa1710895
New England Journal of Medicine · 697 Zitierungen
TLDR
In patients with gout and major cardiovascular coexisting conditions, febuxostat was noninferior to allopurinol with respect to rates of adverse cardiovascular events.